Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24114113 | 0.83 | METAP1 (0.40) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL21644748 | 0.81 | METAP1 (0.39) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL4304797 | 0.80 | KDM4E (0.45) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL25179955 | 0.80 | ATR (0.40) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL30992827 | 0.79 | METAP1 (0.40) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL25180969 | 0.79 | ATR (0.45) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL25179953 | 0.79 | METAP1 (0.38) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL20846078 | 0.75 | METAP1 (0.35) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL15264820 | 0.74 | ATR (0.48) | METAP1ATRCA1CA2PSMB8 | |
| SCHEMBL26848070 | 0.74 | LCK (0.41) | METAP1ATRCA1CA2PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513071-B1 | THIAZOLEDERIVATES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2015-06-17 | — | — | EP | claimed |
| US-12486289-B2 | Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-110958882-B | Tricyclic compounds as glycogen synthase kinase 3 (GSK 3) inhibitors and uses thereof | 布罗德研究所股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220112216-A1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| US-8703961-B2 | Thiazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20140107126-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-17 | — | — | US | disclosed |
| WO-2014041175-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2014-03-20 | — | — | WO | disclosed |
| EP-2513071-A1 | THIAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKER HAFTING (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKER HAFTING (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKER HAFTING (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-102666509-A | Thiazole derivatives for treating diseases such as cancer | MERCK PATENT GMBH | 2012-09-12 | — | — | CN | disclosed |
| WO-2011072779-A1 | THIAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072779-A1 | THIAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112216-A1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | GSK3A, GSK3B, PYGB | METAP1 1489/4885ATR 102/4885CA1 570/4885 |
| US-20120252759-A1 | THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | RET, IGF1R, JAK2 | METAP1 2901/4885ATR 1146/4885CA1 3363/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | METAP1 1200/4885ATR 4143/4885CA1 4877/4885 |
| US-20140107126-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE5A, PDE1A, PDE1B | METAP1 2366/4885ATR 2400/4885CA1 1541/4885 |
| US-12486289-B2 | Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof | GSK3A, GSK3B, PYGB | METAP1 1489/4885ATR 102/4885CA1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.